Lilly reports 79 percent response data. Eli Lilly and Company stock is valued at USD 1.23 trillion

Published on 10/27/2026 at 11:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sofe-M achieved 100 percent disease control on October 24, 2026. Eli Lilly stock costs EUR 1,149.50 on October 27, 2026, 0.50 percent above Xetra close.

Clinical pipeline and valuation

Sofe-M achieved a 79.30 percent confirmed response rate on October 24, 2026.
Lilly raised fiscal 2026 revenue guidance to USD 85.0 billion to USD 87.0 billion.
Eli Lilly stock trades at EUR 1,149.50 at 11:22 a.m. CET at Lang & Schwarz on October 27, 2026, 0.50 percent above the Xetra close of October 26, 2026.

Eli Lilly and Co., US5324571083, Illustration mit AI erstellt.

Lilly reported a 79 percent confirmed response rate for its Sofe-M ovarian cancer program, while Eli Lilly and Company stock carried a USD 1.2 trillion market value on October 26, 2026. The company released the clinical data on October 24, 2026, through Eli Lilly.

Ovarian cancer data move forward

Sofetabart mipitecan, or Sofe-M, plus bevacizumab produced a 79.30 percent confirmed objective response rate among 29 patients with measurable disease as of the July 6, 2026, data cutoff. Disease control reached 100 percent, while 6 percent of participants discontinued treatment because of an adverse event, according to Eli Lilly.

The result came from a 33-woman cohort and supports the ongoing three-part Phase 3 FRAmework-01 program. Pharmaphorum reported that dose reductions occurred in 42 percent of participants, making tolerability an important counterweight to the early efficacy signal.

Three October milestones

On October 18, 2026, Lilly outlined oncology presentations at ESMO, including first Phase 1 Sofe-M data, according to Eli Lilly. On October 22, 2026, the company said its Richmond project was part of 10 new U.S. manufacturing sites since 2020, according to Eli Lilly. On October 24, 2026, it presented the 79.30 percent response rate and 100 percent disease control result.

What comes next for Lilly?

The investor calendar lists the next earnings call for October 29, 2026, followed by Lilly Innovation Day on December 7, 2026, according to Eli Lilly. For the stock, the near-term test is whether the upcoming report can reinforce the oncology pipeline signal alongside the companys obesity and diabetes portfolio.

Stock valuation after the data

Second-quarter 2026 revenue reached USD 23.0 billion, up 47.70 percent from USD 15.6 billion a year earlier, while diluted earnings per share rose 26.20 percent to USD 7.94, according to Stockrow. The same analysis said Lilly raised fiscal 2026 revenue guidance to USD 85.0 billion to USD 87.0 billion from USD 82.0 billion to USD 85.0 billion. Eli Lilly stock was trading at EUR 1,149.50 at Lang & Schwarz on October 27, 2026, at 11:22 a.m. CET, up 0.50 percent versus the Xetra close of October 26, 2026 at EUR 1,143.80. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.